Akums Drugs and Pharmaceutical Cash Flow Conversion Efficiency
Akums Drugs and Pharmaceutical cash flow conversion efficiency. Based on the latest financial reports, Akums Drugs and Pharmaceutical (AKUMS) has a cash flow conversion efficiency ratio of 0.364x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs11.52 Billion ≈ $124.61 Million USD) by net assets (Rs31.68 Billion ≈ $342.65 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Akums Drugs and Pharmaceutical (2022–2026)
Cash flow conversion efficiency of Akums Drugs and Pharmaceutical from 2022 to 2026. This chart illustrates how Akums Drugs and Pharmaceutical's cash flow conversion efficiency has evolved over time, based on yearly financial data. View AKUMS stock price for real-time trading data and today's change.
Akums Drugs and Pharmaceutical Cash Flow Conversion Ratio Explained
Akums Drugs and Pharmaceutical cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Akums Drugs and Pharmaceutical Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Akums Drugs and Pharmaceutical ranked by their cash flow conversion efficiency. Also see Akums Drugs and Pharmaceutical market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hanall Biopharma
KO:009420
|
0.047x |
|
BioGaia AB (publ)
ST:BIOG-B
|
0.046x |
|
Wuxi Paike New Materials Technology Co Ltd
SHG:605123
|
0.063x |
|
Shenzhen Noposion Agrochemicals Co Ltd
SHE:002215
|
-0.058x |
|
FLEX LNG Ltd
F:0QQA
|
0.050x |
|
Preferred Bank
NASDAQ:PFBC
|
0.036x |
|
ATRESM.C.D.M.ADR/1/EO-75
F:YT2
|
N/A |
|
Lloyds Engineering Works Limited
NSE:LLOYDSENGG
|
-0.224x |
Annual Cash Flow Conversion Efficiency for Akums Drugs and Pharmaceutical (2022–2026)
The table below shows the annual cash flow conversion efficiency of Akums Drugs and Pharmaceutical from 2022 to 2026. Review Akums Drugs and Pharmaceutical free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | Rs33.31 Billion ≈ $360.25 Million |
Rs12.11 Billion ≈ $130.94 Million |
0.363x | +139.36% |
| 2025-03-31 | Rs30.64 Billion ≈ $331.32 Million |
Rs4.65 Billion ≈ $50.31 Million |
0.152x | -78.04% |
| 2024-03-31 | Rs7.20 Billion ≈ $77.92 Million |
Rs4.98 Billion ≈ $53.88 Million |
0.692x | +183.22% |
| 2023-03-31 | Rs7.23 Billion ≈ $78.23 Million |
Rs1.77 Billion ≈ $19.10 Million |
0.244x | +379.22% |
| 2022-03-31 | Rs6.25 Billion ≈ $67.61 Million |
Rs318.54 Million ≈ $3.44 Million |
0.051x | -- |
About Akums Drugs and Pharmaceutical
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offe… Read more